Jason Silverston, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1245498609
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 441 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations.
Across 441 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$813
- Corcept Therapeutics$596
- Tandem Diabetes Care, Inc.$574
- Radius Health, Inc.$422
- plus $4K from 33 others
What the payments were for
- Food & beverage$8,94499%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 70 | $1,120 |
| Novo Nordisk | 61 | $1,119 |
| Sanofi-aventis U.S. LLC | 37 | $813 |
| Corcept Therapeutics | 21 | $596 |
| Tandem Diabetes Care, Inc. | 21 | $574 |
| Radius Health, Inc. | 13 | $422 |
| Insulet Corporation | 17 | $409 |
| Boehringer Ingelheim | 19 | $349 |
| Amgen(2 entities) | 18 | $348 |
| BETA Bionics, Inc. | 4 | $337 |
| Xeris Pharmaceuticals, Inc. | 17 | $326 |
| AstraZeneca(2 entities) | 21 | $304 |
| Mannkind Corporation | 13 | $254 |
| Abbott | 11 | $238 |
| Bayer | 12 | $236 |
| Dexcom, Inc. | 12 | $220 |
| Amneal Pharmaceuticals LLC | 10 | $154 |
| Cequr Corporation | 3 | $124 |
| AbbVie | 8 | $110 |
| Sequel Med Tech, LLC | 5 | $103 |
| Ascensia Diabetes Care US Inc. | 5 | $94 |
| Antares Pharma, Inc. | 6 | $93 |
| Johnson & Johnson(2 entities) | 6 | $86 |
| Merck | 6 | $86 |
| Medtronic(2 entities) | 4 | $81 |
| Madrigal Pharmaceuticals | 2 | $69 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Companion Medical, Inc. | 1 | $54 |
| Ascendis Pharma Endocrinology Inc | 3 | $47 |
| IBSA Pharma Inc. | 3 | $45 |
| Valeritas, Inc. | 2 | $30 |
| Almatica Pharma LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Vivus LLC | 1 | $12 |
| Recordati_rare_diseases_inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$730
- Korlym$141
- MOUNJARO$125
- Tymlos$122
- t:slim X2 Insulin Pump with Control-IQ$111
How this compares
$9,017 in reported general payments places this provider in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 343 | $434,061 |
| MounjaroTirzepatide | 135 | $155,158 |
| TrulicityDulaglutide | 102 | $130,835 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 131 | $115,540 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 92 | $96,980 |
| Tresiba Flextouch U-200Insulin Degludec | 76 | $91,951 |
| FarxigaDapagliflozin Propanediol | 88 | $88,593 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 47 | $73,512 |
| ProliaDenosumab | 42 | $72,260 |
| JardianceEmpagliflozin | 65 | $72,080 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $52,519 |
| TymlosAbaloparatide | 18 | $52,269 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $49,429 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 70 | $45,767 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 38 | $39,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $1,119 | $461,799389 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $1,120 | $322,033285 claims |
| Boehringer IngelheimJardiance, Tradjenta | $349 | $102,98191 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $813 | $101,451111 claims |
| AstraZenecaFarxiga | $304 | $88,59388 claims |
| AmgenProlia | $348 | $72,26042 claims |
| Radius Health, Inc.Tymlos | $422 | $52,26918 claims |
| MerckJanuvia | $86 | $27,19319 claims |
| AbbVieSynthroid | $110 | $21,402194 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $154 | $7,263475 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.